News Focus
News Focus
Followers 140
Posts 11663
Boards Moderated 0
Alias Born 03/15/2011

Re: hopefilled2014 post# 266801

Thursday, 06/16/2016 6:42:47 AM

Thursday, June 16, 2016 6:42:47 AM

Post# of 347009
hopefilled, yes, actually more then ever BUT with a year or so delay.

We all know that I-O will make it over chemo because industry and FDA wants its so. Chemo is 'LOADED' and people think immediately at the side effects. I-O has ALSO side effects but for now patients are not aware of that at the same extend. Furthermore for responders this is less a problem as they get better overall. With the companion tests responders can be targetted.

With drugs like Bavituximab in the mix the side effects can be milded and it brings non of its own. The number of responders increases and with the immune activation one can eliminate the risk of getting the same disease again.

That makes it all more worth for the patients because spending 150K$ for an Opdivo treatment were, EVEN IF YOU ARE A RESPONDER, you'll have a big risk to fall back after a few years places a burden on families.

So in the long run there is MORE revenue for PPHM with Bavituximab in I-O if they don't disrupt the market with Chemo Combo's. If Bavi would have been approved in Chemo/Bavi there was more big immediate revenue and that would reflect (or be reflecting now) in the PPS. With the stop of SUNRISE and the year of PI I-O clinical trials PPHM will collect more but over a longer period. It will also put them in 1st place to be for BetaBodies and they will be able to exploit there patents much longer.

You know in the end Microsoft made its break-through with PC DOS that they sold non-exclusive to IBM (and witch is actually a CPM variant from which they bought the rights for pocket money). PPHM holds the rights on the PS targeting and will rentabilize them via BP FIRST then possibly become a BP themselves.

With the current PI strategy they are exactly doing the Microsoft scenario in stead of trying to become BP first. OK they gave it a shot, I was all behind that attempt to go it alone, it failed, now the strategy must be brought back in line. It could have worked but it didn't. The loss is majorly Time & Frustration depending on who evaluates. Of course with hindsight it is all easy to claim they shouldn't have tried but nobody could predict the SUNRISE control arm anomaly because without it they would have passed. So however would claim I told you so should show where they said it would not work because we would have an abnormal control arm in SUNRISE.


Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y